PureTech HealthPRTCY +1.49%62 PS Ratio is 90.41 as of Jun. 24, 2026, which is 17% below its 10-year median of 109.13. GuruFocus rates PRTCY with a GF Score™ of 62/100 and a GF Value™ of $70.09 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 937 Biotechnology companies, PureTech Health ranks worse than 83.78% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, PureTech Health's share price is $17.54.
PureTech Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.19. Hence, PureTech Health's PS Ratio for today is 90.41.
The historical rank and industry rank for PureTech Health's PS Ratio or its related term are showing as below:
PRTCY'
s PS Ratio Range Over the Past 10 Years
Min: 26.4 Med: 109.13 Max: 1170
Current: 88.61
During the past 13 years, PureTech Health's highest PS Ratio was 1170.00. The lowest was 26.40. And the median was 109.13.
PRTCY's PS Ratio is ranked worse than 83.78% of 937
companies
in the Biotechnology industry
Industry Median: 9.36
vs PRTCY: 88.61
PureTech Health PLC revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of PureTech Health was 7.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 32.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -13.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -8.80% per year.
During the past 13 years, PureTech Health's highest 3-Year average Revenue per Share Growth Rate was 119.00% per year. The lowest was -54.30% per year. And the median was -7.60% per year.
Back to Basics: PS Ratio
PureTech Health (OTCPK:PRTCY) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
PureTech Health PS Ratio Related Terms
PureTech Health PS Ratio Historical Data
* Premium members only.
The historical data trend for PureTech Health's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PureTech Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where PureTech Health's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
PureTech Health's Share Price of today is $17.54.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PureTech Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.19.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PureTech Health (PRTCY) has a PS Ratio of 90.41 as of Jun. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on PureTech Health and its competitors. This is 17% below median its historical median of 109.13. Over the past decade, PureTech Health's PS Ratio has ranged from 26.40 to 1,170.00. According to the industry distribution chart, PureTech Health ranks #785 out of 937 companies in the Biotechnology industry, placing it in the top 83.8%.
Is PureTech Health's PS Ratio too high?
PureTech Health's current PS Ratio of 90.41 is 17% below median its 10-year median of 109.13. Over the past 10 years, this metric has ranged from a low of 26.40 to a high of 1,170.00. The Biotechnology industry median PS Ratio is 9.36. PureTech Health's value of 90.41 is 865.9% above this industry median. Based on the distribution chart, PureTech Health ranks #785 out of 937 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #785 out of 937 companies for PS Ratio. This places PureTech Health in the lower half of its industry. The industry median PS Ratio is 9.36. PureTech Health's value of 90.41 is 865.9% above this benchmark. Historically, PureTech Health's own PS Ratio has ranged from 26.40 to 1,170.00 over the past decade. While the company's 10-year median is 109.13 vs. the industry median of 9.36, PureTech Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.36, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current PS Ratio of 90.41 is 865.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on PureTech Health and its competitors. For the Biotechnology industry, the median PS Ratio is 9.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current PS Ratio is 90.41, which is 17% below median its own 10-year median of 109.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current PS Ratio is 90.41, which is 17% below median its 10-year median of 109.13 and 865.9% above the Biotechnology industry median of 9.36. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For PureTech Health (PRTCY), the current PS Ratio is 90.41 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (PRTCY) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for PRTCY:
PS Ratio: 90.41 (17% below median its 10-year median of 109.13)
GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
Industry Position: 865.9% above the Biotechnology median (#785 of 937)
No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score
Get the complete analysis for PRTCY
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRTCY has been successfully added to your 
